This finding opens the door to new cancer research avenues, cancer diagnosis, and antitumor therapeutic strategies using NK-1R agonists/antagonists-based cancer therapy, cytotoxic peptide conjugate-based cancer therapy, or peptide-receptor radionuclide therapy [12,13,14,15,16,17,18,19,20]. The gene discussed is TACR1; the disease is cancer.